---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Pharmacokinetics"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Pharmacokinetics. Topics: Healthy volunteers, single intravenous doses: dose-proportional exposure and terminal half-life; Healthy volunteers, single subcutaneous doses of 50 to 600 mg; Nonclinical pharmacokinetics in cynomolgus macaques: effect of the YTE substitutions; CSU, multiple doses: dose-linear exposure, accumulation, and target saturation; 4 further topics. 8 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/pharmacokinetics"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Pharmacokinetics

<a id="heading-2.1.2.6.3"></a>

## 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

### Healthy volunteers, single intravenous doses: dose-proportional exposure and terminal half-life

> “A single dose of CDX‐0159 at 0.3, 1, 3, and 9 mg/kg, or placebo was intravenously administered to healthy subjects (Table 1).”
> “CDX‐0159 serum levels were dose proportional and indicative of a PK profile with high exposure and long half‐life at higher doses, consistent with the expected effects of the YTE substitutions (Figure 4A and Table S2).”
> “Mean terminal phase half‐life increased from 15 days at 0.3 mg/kg to 32 days at 9 mg/kg, which exceeds the average expected half‐life of 10–21 days for human IgG”
> “Results indicate a PK profile and volume of distribution consistent with those of a monoclonal antibody through this dosing range with evidence of target mediated clearance below approximately 5 μg/ml.”
> “For example, the terminal half‐life of CDX‐0159 at a single 3 mg/kg dose was 23 days and was accompanied with tryptase suppression for >6 weeks.”

Source: [Alvarado et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9544977/)

> “This study will evaluate the safety, pharmacokinetics, and pharmacodynamics of CDX-0159 in healthy subjects.”

Source: [ClinicalTrials.gov NCT04146129](https://clinicaltrials.gov/study/NCT04146129)

<a id="topic-2.1.2.6.3-2"></a>

### Healthy volunteers, single subcutaneous doses of 50 to 600 mg

> “The randomized, double-blind, placebo-controlled Phase 1 study will evaluate single ascending doses of CDX-0159 administered subcutaneously in healthy volunteers.”
> “Thirty two subjects will be enrolled across four dosing cohorts (50 mg, 150 mg, 300 mg and 600 mg) with 8 subjects in each cohort (6 active; 2 placebo).”
> “The primary endpoints of the study are safety and tolerability; secondary endpoints include pharmacokinetics, pharmacodynamics (circulating tryptase and stem cell factor) and immunogenicity.”

Source: [Celldex subcutaneous formulation study release (2021)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-initiation-cdx-0159-subcutaneous-formulation)

> “CDX-0159 serum concentrations will be measured at specified visits”
> “Patients will be monitored for the development of anti-drug antibodies.”

Source: [ClinicalTrials.gov NCT05031624](https://clinicaltrials.gov/study/NCT05031624)

> “Multiple dose levels have been identified that possess promising pharmacokinetic and pharmacodynamic properties.”
> “Celldex anticipates the upcoming Phase 2 multi-dose studies in urticaria will evaluate 75mg and 150mg administered q4weeks and 300mg administered q8weeks.”
> “The planned doses support a 0.5 to 2 ml injection volume, allowing for a single injection as CDX-0159 advances towards potential commercialization.”

Source: [Celldex fourth quarter 2021 results release (2022)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-fourth-quarter-and-full-year-2021-financial)

<a id="topic-2.1.2.6.3-3"></a>

### Subcutaneous bioavailability, time to peak concentration, and half-life

No evidence found.

<a id="topic-2.1.2.6.3-4"></a>

### Nonclinical pharmacokinetics in cynomolgus macaques: effect of the YTE substitutions

> “Consistent with previously published data with antibodies harboring YTE mutations, the pharmacokinetic properties of CDX‐0159 in cynomolgus macaques were indeed enhanced relative to CDX‐0158”
> “terminal half‐life (22 ± 5.8 vs. 4.8 ± 3.5 days)”

Source: [Alvarado et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9544977/)

<a id="topic-2.1.2.6.3-5"></a>

### CSU, multiple doses: dose-linear exposure, accumulation, and target saturation

> “Given the sustained tryptase suppression and prolonged serum half‐life observed in the single‐dose study, two dose schedules were evaluated: once every 4 weeks (Q4W) and every 8 weeks (Q8W).”
> “PK parameters were calculated using noncompartmental methods and summarized using descriptive statistics to compare exposure in single and multiple dose settings.”
> “Multiple doses of barzolvolimab resulted in prolonged exposure through 24 weeks in the ≥ 1.5‐mg/kg dose levels (Figure 2A).”
> “Maximum serum concentration (Cmax) and AUC increased in a linear fashion with increasing dose (Table S1).”
> “Increased clearance and lower volumes of distribution were observed in patients who received lower doses.”
> “Barzolvolimab levels accumulated through multiple dosing cycles at all dose levels, and exposure by Cmax and AUC increased linearly with dose.”
> “Target saturation was observed with a durable clinical response and tryptase suppression with doses ≥ 1.5 mg/kg.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-2.1.2.6.3-6"></a>

### Chronic inducible urticaria, single 3 mg/kg intravenous dose: clearance, half-life, volume of distribution, and time to clearance

> “Single-dose barzolvolimab administration exhibited a slow rate of clearance (2.7 ± 0.9 ml/day/kg) and a terminal half-life of 20.1 ± 7.1 days, consistent with engineered half-life extending mutations.”
> “The volume of distribution in the terminal phase was 70.9 ± 7.1 ml/kg or approximately 4.9 L in a 70 kg human.”
> “There were no differences in PK parameters between CU and SD patients and exposure was very similar to that observed in healthy volunteers (Figure 1A).”

Source: [Terhorst-Molawi et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/all.15585)

> “Barzolvolimab pharmacokinetics in patients with CIndU (N = 20) following a single 3 mg/kg intravenous dose.”
> “Drug levels reach approximately 1 μg/mL by Week 12, as MC markers and clinical symptoms start to recover.”
> “Barzolvolimab is fully cleared after Week 18.”

Source: [Alvarado et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12862557/)

<a id="topic-2.1.2.6.3-7"></a>

### Prurigo nodularis, single intravenous dose: terminal half-life and exposure by sex, weight, and antidrug antibody status

> “We report the effect of a single dose of barzolvolimab, on safety, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity, in patients with PN.”
> “Adults with moderate-to-severe PN were randomly assigned in a 1:1:1 ratio to placebo or barzolvolimab at 1.5 or 3.0 mg/kg as an intravenous infusion and were followed for 24 weeks.”
> “The mean terminal phase half-life was 10.2 ± 3.0 days in 1.5 mg/kg and 18.0 ± 6.9 days in 3.0 mg/kg barzolvolimab-treated participants”
> “Exposure was not influenced by intrinsic and extrinsic participant-specific parameters, including sex, weight, or treatment-emergent antidrug antibody status”

Source: [Metz et al. (2025d)](https://doi.org/10.1016/j.jaad.2025.08.022)

<a id="topic-2.1.2.6.3-8"></a>

### CSU: barzolvolimab concentrations during the 24-week follow-up period of the phase 2 trial

> “In a Phase 2 trial of patients with antihistamine-refractory CSU treated with barzolvolimab (150 mg Q4W or 300 mg Q8W for 1 year), 71% had well controlled disease at the end of the treatment period”
> “Following a 52-week total treatment period, patients entered a 24-week follow-up period”
> “Concentration of barzolvolimab falls below therapeutic levels by week 64”
> “Maintenance of well-controlled disease despite subtherapeutic concentrations of barzolvolimab”

Source: [Metz et al. (2026b)](https://celldex.com/wp-content/uploads/2026/02/Barzol_AAAAI-CSU-OT-Analysis-2.27.26.pdf)

<a id="topic-2.1.2.6.3-9"></a>

### Immunogenicity: treatment-emergent antidrug antibodies and their effect on exposure and safety

> “The impact of antidrug antibodies (ADA) on drug levels and safety was evaluated by comparing the area under the concentration–time curve (AUC) and the incidence of AEs for ADA‐positive versus ADA‐negative patients in each treatment group, respectively.”
> “Fifty‐seven percent (20/35) of patients were ADA positive, and the proportion of patients who experienced drug‐related AEs was similar in ADA‐positive and ADA‐negative patients.”
> “Treatment‐emergent ADA were observed in 57% of barzolvolimab‐treated patients, without apparent impact on exposure.”
> “Antibarzolvolimab antibodies did not appear to impact the safety parameters in this study.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-2.1.2.6.3-10"></a>

### Immunogenicity in the phase 2 and phase 3 CSU trials

No evidence found.

Additional sources: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
